If you are having trouble reading this email, read the online version.

Easy access to the most accurate testing

Better accuracy in SARS-CoV-2 (COVID-19) molecular (NAAT) testing means providing higher levels of sensitivity1 and detecting the latest genetic variants.2

At Quest, we’ve worked relentlessly to excel at those metrics while also ensuring the test is available to as many people as possible. Your patients have access to our robust network of:

Car illustration

Convenient drive-up locations

Lab coat illustration

Walmart® and CVS Health® partnerships for additional testing sites

Credit card illustration

At-home collection kits available through QuestDirect

Calendar illustration

High-capacity laboratories that deliver accurate results in 1-2 days or less



SARS-CoV-2 RNA (COVID-19), Qualitative NAAT
Test code: 39448


$0 out-of-pocket and low-cost COVID-19 testing

A simple online process helps your patients find out if they are eligible for no-cost COVID-19 testing that is covered by their health plan or the government. New policy now makes coverage for testing asymptomatic patients available as well. Affordable self-pay options are also available. Learn more arrow


Safer routine lab testing

When your patients require routine lab testing, they can rely on Quest. Our 2,200+ patient service centers have enhanced safety precautions in place, including mobile check-in and many with wait by text options. New guidelines also encourage patients to schedule appointments instead of walking in. Learn more arrow

Woman receiving swab test

Taking action against health disparities

Through Quest for Health Equity, we’re providing COVID-19 testing and financial support for the underserved groups and communities hit hardest by the pandemic.

To advance this initiative and make meaningful change, we need partners like you to join us.


Contact your sales representative for more information at 1.866.MYQUEST (1.866.697.8378).



1 Center for Devices and Radiological Health. Genetic variants may lead to false negatives with SARS-CoV-2 molecular tests for detection of SARS-CoV-2. Published January 8, 2021. https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2#:~:text=Molecular%20tests%20are%20typically%20highly,of%20SARS%2DCoV%2D2

2 CDC. SARS-CoV-2 Reference Panel Comparative Data. (Based on calculations from data in Table 2A.) Content current as of December 7, 2020. Accessed February 12, 2021. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data#results